LUNAI BIOWORKS INC

LNAINASDAQ

🏆 #4564 by market capUS Equity

$2.33▼ $0.07 (−2.92%)

Live

1h▼ 1.3%

24h▼ 2.9%

7d▼ 7.2%

14d▲ 9.9%

30d▼ 20.1%

1y▼ 87.7%

🏦Market Cap

$11M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $2.30 – $2.35
52-Week Range: $1.21 – $21.20
Volume: $2.98B
Avg Volume: $3.50B
Shares Outstanding: 4.5M
Next Earnings: Oct 28, 2026

Fundamentals Snapshot

Annual Revenue: $793,602
Last Q Revenue: $20,942
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-7.63
Dividend Yield: —

Why Investors Own LNAI

✓High-growth profile — revenue up +5.8% YoY with expanding US Equity exposure.
✓Healthy economics — 57% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$793,602▲ +6.8% YoY

Gross Margin (TTM)

57.0%▲ +1.2% YoY

Operating Income (TTM)

$253,952▲ +6.8% YoY

Free Cash Flow (TTM)

$125,389▲ +6.8% YoY

About LUNAI BIOWORKS INC

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

🦦